medigraphic.com

2020, Number 1

<< Back Next >>

Rev Hematol Mex 2020; 21 (1)

Prevalence of multiple myeloma in a national hospital of reference of Mexico City from 2011 to 2016

Martínez-Cornejo TL, Nájera-Martínez J, Torres-Alarcón CG, Hernández-Bueno AI, García-Castillo C, Campos-Cortés Á, Carrillo-Jurado Á, Ruiz-Martínez MC

Language: Spanish
References: 22
Page: 32-40
PDF size: 428.91 Kb.


ABSTRACT

Background: Multiple myeloma is a malignant neoplasia characterized by uncontrolled proliferation and accumulation of plasma cells in the bone marrow, associated with production of a monoclonal protein. It accounts for around 10% of all haematological malignant neoplasias.
Objective: To know the prevalence of multiple myeloma in a third level hospital in Mexico City.
Material and Method: An observational, descriptive, retrospective, crosscut study was conducted from 2011 to 2016, in patients with diagnosis of multiple myeloma.
Results: In the 6-year study, 93 new cases were registered. The number of new cases ranged between 12 and 18 per year, with a mean age of 63.06 ± 10.3; the most affected group was that of 54 to 73 years old, who made up 73% of all cases. The disease was more frequent in men (64.5%) than in women. No statistically significant differences were found in paraclinical studies at diagnosis between males and females. Anemia was present in 75.3% of cases, with men being more affected than women.
Conclusions: Prevalence of multiple myeloma in the haematology service of a third-level hospital was of 8.5%. Prevalence in this hospital is 33.4 per each 100,000 patients seen and 2.13 per each 100,000 rightful claimants.


REFERENCES

  1. Peller PJ. Multiple myeloma. PET Clin 2015 Apr;10(2):227- 41. doi: 10.1016/j.cpet.2014.12.008.

  2. Kyle RA, Steensma DP. History of multiple myeloma. Recent Results Cancer Res 2011;183:3-23. doi: 10.1007/978-3- 540-85772-3_1.

  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-86. doi: 10.1002/ijc.29210.

  4. Díaz-Maqueo J. Historia del mieloma múltiple. Rev Biomed 2006;17(3):225-229.

  5. Poder Legislativo Federal Comisión Permanente. Pod Legis Fed Com Perm Segunda Com Relac exteriores, Def Nac y Educ Pública. 2017. http://www.senado.gob.mx/ sgsp/gaceta/63/2/2017-08-23-1/assets/documentos/ Dict_2da_Inclusion_Educativa.pdf. Accessed May 2, 2018.

  6. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11):1046-1060. doi: 10.1056/NEJMra1011442.

  7. Zink A, Rohrbach H, Szeimies U, Hagedorn HG, Haas CJ, Weyss C, Bachmeier B, Nerlich AG. Malignant tumors in an ancient Egyptian population. Anticancer Res 1999 Sep- Oct;19(5B):4273-7.

  8. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-e548. doi: 10.1016/S1470- 2045(14)70442-5.

  9. Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol 2016;97(5):416-429. doi: 10.1111/ejh.12790.

  10. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842- 854. DOI: 10.1002/1097-0142(197509)36:3<842::aidcncr2820360303> 3.0.co;2-u

  11. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al. International staging system for multiple myeloma. J Clin Oncol 2005;20;23(15):3412-20. DOI: 10.1200/ JCO.2005.04.242.

  12. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-55.

  13. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw 2018;16(1):11-20. https:// doi.org/10.6004/jnccn.2018.0002.

  14. Barrios Hernández IL GMJ. Presentación clínica del mieloma múltiple en pacientes de un hospital regional. Rev Esc Med Dr. Jóse Sierra Flores 2013;27(1):16-20.

  15. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Multiple myeloma. Nat Rev Dis Primer 2017;3:1-20. doi: 10.1038/nrdp.2017.46.

  16. Bladé J, Kyle RA. Multiple myeloma in young patients: Clinical presentation and treatment approach. Leuk Lymphoma 1998;30(5-6):493-501. DOI: 10.3109/10428199809057562.

  17. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ruiz-Delgado GJ, Aguilar-Romero L. Multiple myeloma in Mexico: a 20-year experience at a single institution. Arch Med Res 2004;35(2):163-167. DOI: 10.1016/j.arcmed. 2003.09.013.

  18. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos M-A. Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 2006;47(5):803-814. DOI: 10.1080/10428190500464104.

  19. Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk Res 2007;31(2):129-138. DOI: 10.1016/j.leukres.2006.04.014.

  20. Healy CF, Murray JG, Eustace SJ, Madewell J, O’Gorman PJ, O’Sullivan P. Multiple myeloma: a review of imaging features and radiological techniques. Bone Marrow Res 2011. https://doi.org/10.1155/2011/583439.

  21. Valencia Huerta O, Valenzuela Duarte AJ, Ortiz Contreras K, Romo Aguirre C, Zarate Osorno A, Gomez-Perez MG, Hurtado Monroy R. Localización inusual de lesiones líticas de mieloma múltiple con resonancia magnética. Rev Fac Med UNAM 2015;58(1):40-47.

  22. Contte M, Isnardi S, Sieza Y. Enfermedad ósea en el mieloma múltiple. Rev Arg de Hemat 2010;14(2):29-40.




2020     |     www.medigraphic.com